OpusPoint Partners: Trailblazers of the Healthcare and Life Sciences Revolution

0 comments

Posted on 12th September 2011 by emorgan in Lindsayrosenwald

,

When OpusPoint Partners was started in 2009 by Michael S. Weiss and Dr. Lindsay Rosenwald it was then just one of a number of biotechnology companies founded by these two men who have jointly had more than 40 years combined experience and expertise in the area of investing in biotechnological research.

Today, OpusPoint Partners has retained its position at the forefront of the life science and healthcare industries, revolutionizing the way that money is allocated towards investments for the advancement of healthcare and life sciences with a view to improving the quality of life for people from all over the world. The company is confident that under the dual leadership of these two gentlemen, the healthcare industry will improve how diseases are diagnosed and how healthcare treatment is delivered to patients to continue to meet the needs of the patients more effectively.

OpusPoint Partners under the guidance of Dr. Lindsay Rosenwald has stood steadfast in its commitment to practice integrity and still attain all of its short and long term goals. They seek to form a team which includes both the investors and the researchers working together in a quest to advance the future of medical care. Working relationships such as these which bring together the investment with the biotechnology build on a foundation of trust that brings out a high measure of honesty in the investing and full disclosure in all the related company’s dealings. This is where the team put together by OpusPoint Partners is then able to discover emerging companies and invest funds and resources into these enterprises where promising results are already being seen in the fields of healthcare and life sciences.

There is fierce competition in this industry and as a result OpusPoint Partners has established a solid conglomeration of organizations that know that it is easy to get lost by employing tactics that are not very ethical, in order to beat the system and to improve their earnings when performing clinical trials. This conglomeration maintains its guiding principles which sticks to its integrity and forfeits the dangerous short cuts. This is the essence that makes OpusPoint partners unique, being fair and loyal to its employees and its investors and not compromising when it comes to the research and the development of drugs through all of the trial stages and the final manufacturing stages.

These policies ensure that OpusPoint Partners will continue to be trailblazers, providing invaluable assistance for public companies and for businesses that are now starting up. This assistance comes in the form of advisory services and investments, believing that the mission to improve innovative companies bring a corresponding increase in the volume of medical breakthroughs which occur and having a ripple effect of improving the lives of many people.

The commitment and dedication to improving the way in which biotech investing is done is maintained by imposing strong moral values and by using strong business practices. Investors are then afforded excellent returns with minimal risk, a straight forward formula that proves the worthiness of this methodology. The success of this commitment has not gone without its rewards. Dr. Rosenwald highlighted that in the past few years, the company far exceeded its performance projections and was instrumental in significantly improving the financial health of more than twenty companies, earning them excellent accolades in the areas of drug research and finance and also earning excellent risk adjusted returns for its investors.

The mission of transforming present day healthcare and medical techniques and procedures as expected is not an easy undertaking. Time and commitment backed with hard work will support the provision of funding and bring promising results without compromising the ethical standards of the industry or losing earnings.

Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition and has formed many allegiances with many key individuals in the biotechnology financial sector. His illustrious career includes more than seventeen years as a Wall Street biotechnology investor. Dr. Rosenwald also founded the company Cougar Biotechnology Inc. in Los Angeles which is focused on the production of experimental drugs that treat cancer. One of these drugs has had remarkable success because of its effectiveness in the treatment of late stage prostate cancer. Johnson & Johnson acquired Cougar Biotech Labs on July 10th 2009 at a cost of over one billion dollars.

Dr. Lindsay Rosenwald managed the Aries Funds from 1994 to 2007 and this fund in the Year 2000, administered over $1B in healthcare investments. He also managed the Orion Fund from 2002 to 2006 which is a committed capital fund which is dedicated to private investments in biotechnology which also includes the PIPEs. With this wealth of experience come a medical degree from the Temple University School of Medicine and a finance degree from the Pennsylvania State University.

Dr. Rosenwald has established and re-capitalized quite a number of private and public sector biotechnology and life sciences companies. OpusPoint Partners anticipates that under his joint leadership, its successes will continue to set the trails ablaze well into the future.

OpusPoint Partners: Making New Discoveries in Biotechnology

0 comments

Posted on 9th September 2011 by emorgan in Lindsayrosenwald

,

OpusPoint Partners was co-founded in 2009 by Lindsay Rosenwald, M.D., and Michael Weiss. This revolutionary joint venture was to be one that assisted in putting a necessary focus on the growth of emerging biotechnology and life science companies. The promising studies and trials performed by these up and coming biotech firms are what potentially can stamp out life threatening illnesses around the world.

Rosenwald and Weiss recognized the need to support the efforts of these developing companies and through OpusPoint Partners they are able to make the ideal notion of a world with less disease a possibility.

Both men have an overwhelming passion for creating and buttressing biotechnology and life science studies, and each has done so for over 20 years respectively. Lindsey Rosenwald and Michael Weiss have both independently and jointly invested in the development of biotech companies, helping them grow with their expertise and finely tuned ethic compass. It is their desires to not only see these life science and biotech firms succeed but to do so justly without deception.

Lindsay Rosenwald brings his extraordinary knowledge of both finance and biotechnology into play with OpusPoint Partners. Dr. Rosenwald has accomplished much in both his academic life and professional career. He holds two degrees, a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.

Beyond Rosenwald’s academic achievements, he is a successful entrepreneur in the biotechnology field. He has been the driving force behind nearly 50 biotech companies over the span of 20+ years. One of these successful ventures was Cougar Biotechnology Inc., which among its many intriguing studies and drug trials a notable drug that helped thwart the growth prostate cancer in the late stages was discovered. In 2009 Lindsay Rosenwald sold Cougar Biotechnology to Johnson & Johnson for roughly one billion dollars. It is around this time that Rosenwald and Weiss teamed up for a new endeavor together.

With Dr. Rosenwald’s track record it is safe to say that that he has a knack for creating biotech success. Over the last few years with OpusPoint Partners he has aided approximately 20 biotech companies expand their businesses and studies to an extent that would have not been fathomable without the positive backing from the co-founders of this remarkable biotechnology investing firm.

OpusPoint Partners through the assistance of Lindsay Rosenwald as well as other biotech and life science investors are trying to bring a change to the field of drug development by giving biotech companies a fighting chance to make a positive impact in the world of medicine. This desire to influence innovation is based on strong ethical standards and a shared belief that integrity and advance technological thinking is what makes a good biotech business thrive.

This biotechnology investing company doesn’t solely work on their own, OpusPiont Partners also works alongside other investors, researchers, and corporations to find and contribute to the development of biotechnology firms that have great aspirations and ideas but lack the financials and bureaucratic know how to achieve their scientific goals. Lindsay Rosenwald is there to act as a guiding force pathing the way for emergent biotech companies to make a splash in the discovery of life saving drugs.

Dr. Rosenwald has proven time and time again that he is more than adept at making and administrating appropriate investments that are beneficial all around the board. Prior to his time at his current position he managed the Aries Fund (1994 or 2007) and the Orion Fund (2002 to 2006), both of which have made substantial contributions to furthering the efforts of biotechnology and life science companies and their initiatives.

Investors can be sure that with Lindsay Rosenwald managing their investments their risks will be minimal. Rosenwald and Weiss specifically hand pick biotech companies that show not only promise of positive investment growth but also of potentially successful drug research and trials. OpusPoint Partners are committed to staying true to their integrity on both the financial and science areas. A motto of prevailing honesty and discretion is what keeps investors with this company.

OpusPoint Partners sets itself apart from the competition by way of Rosenwald and Weiss’ dedication to remain transparent with their investors and being unyielding in their expectations for ethical research and trials of potentially lifesaving medicine. This steadfastness combined with the immense competency both men bring to the company ensures that OpusPoint Partners will experience continued progression and be a part of necessary discoveries in the biotech industry.

In less than two years at OpusPoint Partners, Lindsay Rosenwald has assisted in financing and mentoring more than 20 biotech companies through his robust financing connections in the biotechnology and life science sectors. OpusPoint Partners still has much more to accomplish and it is obvious that this company is in for a steady run of growth in the years to come.

Lindsay Rosenwald activities outside of his career include being a member of the Board of Directors of the Republican Jewish Coalition.

Lindsay Rosenwald New Investment

0 comments

Posted on 8th June 2011 by admin in Lindsayrosenwald

OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

« Older Entries

Optimized by SEO Ultimate